MedTrace Logo

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

NCT02379377 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-09

No results posted yet for this study

Summary

This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.

Conditions

  • Adult Hepatocellular Carcinoma
  • Resectable Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Benign Liver Tumor
  • Metastases to Liver

Interventions

BIOLOGICAL

Fluorine F 18 L-glutamate Derivative 18F-FSPG

Undergo 18F-FSPG PET scan

BIOLOGICAL

Carbon C 11 Acetate

Undergo 11C-acetate PET scan

PROCEDURE

Positron Emission Tomography

Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose

Undergo 18F-FDG PET scan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Simone S Krebs, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02379377 on ClinicalTrials.gov